Navigation Links
Thermo Fisher Scientific Selected by China Doping Control Center to Supply Testing Instrumentation for the 2008 Olympic Games in Beijing

WALTHAM, Mass., Dec. 3 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that the China Doping Control Center (CDCC) has selected the company as one of its major suppliers of instrumentation and software for the testing of athletes at the 29th Olympic Games in Beijing. The CDCC has been accredited by the Chinese government and the International Olympic Committee (IOC) to conduct all doping control analyses during the 2008 Summer Olympics.

The company will provide the CDCC with a range of high precision and high performance Thermo Scientific brand mass spectrometry (MS) instruments, including DFS Sector Field GC/MS systems, the DELTA V isotope ratio mass spectrometer and triple-quadrupole TSQ Quantum(TM) Access LC/MS systems. These instruments and associated software will enable the CDCC to respond to the high volume of samples expected at the Summer Olympics. Thermo Fisher has also agreed to provide technical and application assistance to the CDCC to ensure uninterrupted operation and secure handing of athlete samples throughout the event.

"Identifying illegal performance-enhancing substances that are used in sports competition is a growing global challenge -- one made even more difficult by the development of sophisticated drugs that are increasingly difficult to detect," said Marijn E. Dekkers, president and chief executive officer of Thermo Fisher Scientific. "Our analytical instrumentation is ideally suited to meet this challenge, providing the high specificity and sensitivity, high throughput and reliability required in today's sports environment."

The CDCC testing program will start before the opening of the competition, and continue from the athlete check-in at the Olympic Village until the end of the games. All samples will be analyzed strictly in accordance with the IOC anti-doping rules for banned substances.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With an annual revenue rate of more than $9 billion, we employ 30,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit

The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward- looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 29, 2007, under the caption "Risk Factors," which is on file with the Securities and Exchange Commission and available in the "Investors" section of our Website under the heading "SEC Filings." We also may make forward-looking statements about the benefits of the merger of Thermo Electron and Fisher Scientific, including statements about future financial and operating results, the new company's plans, objectives, expectations and intentions and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the risk that the businesses will not be integrated successfully; the risk that the cost savings and any other synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; dependence on customers' capital spending policies and government funding policies; realization of potential future savings from new productivity initiatives; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations; the effect of exchange rate fluctuations on international operations; the effect of laws and regulations governing government contracts; the effect of competing with certain of our customers and suppliers; and the effect of rapid changes in the healthcare industry. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Media Contact Information:

Lori Gorski

Phone: 781-622-1242


Investor Contact Information:

Ken Apicerno

Phone: 781-622-1111



SOURCE Thermo Fisher Scientific Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
2. Thermo Fisher Scientific to Present at Investor Conferences
3. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
4. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
5. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
6. Thermo Fisher Scientific to Present at Upcoming Investor Conferences
7. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
8. Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services
9. Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, October 25, 2007
10. Thermo Fisher Scientific Acquires Leader in Micro-Volume Spectrophotometers, NanoDrop Technologies
11. Thermo Fisher Scientific to Expand Manufacturing Operation for Single-Use Bioprocessing Containers
Post Your Comments:
(Date:11/26/2015)... , England , November 26, 2015 ... Lightpoint Medical, an innovative medical device company specializing in imaging ... grant from the European Commission as part of the Horizon ... the company to carry out a large-scale clinical trial in ... -->      (Logo: , --> ...
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
Breaking Biology News(10 mins):